All In Biotech

Drug Trial Radar · NCT03250325

Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients with Synovial Sarcoma

Multi-center Phase I/II Study of NY-ESO-1 T Cell Receptor Gene Transferred T Lymphocytes in Patients with Synovial Sarcoma

Last checked: Nov 20, 2026Latest source record: Nov 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8

Actual

Start

Sep 20, 2017

Primary completion

Jan 23, 2020

Study completion Mar 9, 2022

Sponsor

Lead sponsor
Takara Bio Inc.Industry
Sponsor type
Industry
First posted
Aug 15, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and the efficacy of TBI-1301 for NY-ESO-1 expressing synovial sarcoma when administered following cyclophosphamide pre-treatment.

Conditions

  • Synovial Sarcoma

Interventions

  • TBI-1301Biological

    Split dose of TBI-1301 is administered intravenously for 2 days following cyclophosphamide pre-treatment.

  • CyclophosphamideDrug

    Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. (Phase I) Adverse event, mortality, severe adverse event, discontinuation due to adverse event, laboratory test valuesTime frame: 52 weeks
  2. (Phase I) Appearance of replication competent retrovirus (RCR) by PCRTime frame: 52 weeks
  3. (Phase I) Appearance of clonality by linear amplification mediated (LAM)-PCRTime frame: 52 weeks
  4. (Phase I) Blood kinetics of TBI-1301 by realtime-PCRTime frame: 52 weeks
  5. (Phase II) Overall response rateTime frame: 52 weeks

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Kyushu University Hospital

    Fukuoka, Japan

  • Sapporo Medical University Hospital

    Sapporo, Hokkaido, Japan

  • Mie University Hospital

    Tsu, Mie-ken, Japan

  • National Hospital Organization Osaka National Hospital

    Osaka, Osaka, Japan

  • National Cancer Center Hospital

    Chuo-ku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.